top of page

NEWS
3 days ago
We Work For Health Applauds Senate Introduction of the EPIC Act
Legislation would address the “pill penalty” and strengthen U.S. leadership in pharmaceutical innovation. WASHINGTON, D.C. (March 6,...
Feb 25
We Work For Health Applauds Lawmakers for Re-introducing the Ensuring Pathways to Innovative Cures (EPIC) Act
Bipartisan legislation would correct the IRA’s “pill penalty,” which will have a chilling effect on the prescription drug ecosystem...
Jan 17
Second Round of Medicare Drug Price Controls Perpetuates Flawed, Harmful Policy
FOR IMMEDIATE RELEASE JAN. 17, 2025 WASHINGTON, DC (Jan. 17, 2025) – The Centers for Medicare and Medicaid Services’ (CMS) announcement...
Oct 9, 2024
New Study: Patients Unlikely to See Out-Of-Pocket Drug Savings from IRA
Washington, DC – New research contradicts promises of savings at the pharmacy counter for Medicare beneficiaries from the Inflation...
Jun 9, 2024
New Data Reveals Strong Economic Impact of Texas Biopharmaceutical Industry
For Immediate Release June 5, 2024 Contact: Lisa Glass 512-695-3569 / lglass@rosscomm.com New Data Reveals Strong Economic Impact of...
Jan 18, 2024
New Study Reinforces That Expansion of IRA Price Setting Would Further Crush Patient Health, Innovative Treatments and U.S. Biopharma Jobs
The Latest Plan from Some House Democrats to Expand Government Drug Price Controls Will Lead to Further Declines in New Treatments for...
Aug 8, 2023
Dan Leonard Named Executive Director of We Work For Health
FOR IMMEDIATE RELEASE August 8, 2023 Washington, DC – At a time when preserving America’s leadership in life sciences innovation is...
Jul 7, 2023
CMS Final Guidance on Government-Mandated Drug Pricing Highlights Need for Renewed Focus on...
CMS Final Guidance on Government-Mandated Drug Pricing Highlights Need for Renewed Focus on Patients, Jobs and Cures Latest Announcement...
Jun 14, 2023
New Study Projects Devastating Losses to Drug Develop., Jobs & Patient Health in Biopharma Ecosystem
Washington, DC – A new study estimates that there would be 237 fewer FDA approvals of new medicines for patients battling cancer,...
bottom of page